ADJUVANT

Clinical trials for ADJUVANT explained in plain language.

Never miss a new study

Get alerted when new ADJUVANT trials appear

Sign up with your email to follow new studies for ADJUVANT, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1 Not yet finished but already full! 1 Completed 1

New pill plus chemo aims to stop lung cancer comeback in patients with rare mutations

Disease control Ongoing

This phase 3 trial tests whether adding the targeted drug zipalertinib to standard chemotherapy can delay or prevent lung cancer from returning in people with early-stage non-small cell lung cancer (stages IB to IIIA) who have uncommon EGFR mutations. After complete tumor removal…

Matched conditions: ADJUVANT

Phase: PHASE3 • Sponsor: Taiho Oncology, Inc. • Aim: Disease control

Last updated Jun 28, 2026 00:00 UTC

ADJUVANT

Get alerted when new ADJUVANT trials appear

New pill plus chemo aims to stop lung cancer comeback in patients with rare mutations